byLisbon,February 3rd,2016

It’sallaboutaTeam…

PhDBiomedicinePost.Doc

Fátima Martins

MSc.BiochemistryPhD Candidate

João Silva

LeakyGut,anemergingdisease

InflammationMalabsorption

TissueDamaging

LeakyGut,anemergingdisease

InflammationMalabsorption

TissueDamaging

LeakyGut,anemergingdisease

• Diabetes• Obesity• ColonCancer• FattyLiver

(NAFLD)• GutSyndrome• CeliacDisease

Normal

LeakyGut&Permeability

Blood-flow

Intestinalwall

Normal

LeakyGut&Permeability

Blood-flow

Intestinalwall

Dietary,behavioural andgenetic factors

Blood-flow

Intestinalwall

Pathological

Pro-inflammatoryagentsBacterialproducts

Deleteriousnutrients

TheNeed…Detectearlytoprevent

• SpecificDietInterventions

• SpecificProbiotics

• EmergingDrugs

TreatLeakyGut

• Early intestinalpermeabilitydetection

• High-throughputapplicationmethod

Healthcareneeds

Non-toxic

AnovelmethodIntestinal

PermeAbility Kit

Perme bility

Blood-flow

Blood-flow

Feces

1

2

3

Non-toxic

IntestinalPermeAbility Kit

Perme bility

1

2

3

Blood-flow

Blood-flow4

Anovelmethod

Non-toxic

IntestinalPermeAbility Kit

Perme bility

1

2

3

Blood-flow

Blood-flow4

Anovelmethod

Urine

Quantitativedetection

Bladder

5

• Privatehospitalsandspecializedclinics(entrymarket)

• PreventionandScreeningHealthCentres (early adopters)

• PublicHospitals,ClinicsandHealthCenters(latemajority)

Customers

PopulationCoverage

Obese/Overweightindevelopingcountries Obese/Overweightindevelopedcountries

1Billion

0.9Billion

WHO– 2014data

CompetitorsbutnotthreatsProductfeatures/customerbenefits

ComplexSugars Biopsy Imaging PermeAbility

Earlydetection + + + +++

Accuracy ++ + + +++

TargetPopulation + + + +++

Cost ++ + + +++

Non-invasive ++ + + +++

Timetoresult 2-5days 2-5days immediate 2h

Theroad…

<

Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan2016

Supplierssorting

IPstrategyreportSearchanalysis

Legal&regulatoryconsultancy

HumantrialsCompound productionEthics documentationSample analysis

OtherrelatedcostsM1:decisiononcompoundandpackageproducer

M2:proof-ofconceptinhumans

M3:IPprotectionandlegal&regulatoryreports

2017

€ 100k

Short-termroadmap

ExitStrategy

TRADESALE

Imagingtrackerforintestinallesions(PermeAbilityderived)

Bloodbrainbarrierleakageassessment(PermeAbilityderived)

Non-invasiveinternaltissuesmetabolismsimulation

Pipeline

Point-of-carePermeAbility test

Semi-finalistsofOneStart Europe2015,LondonUK

Prizeof2500€ fromthePortugueseSocietyofDiabetology,February2015

€ 100kinvestment

COHiTECentrepreneurshipdevelopmentprogramcertification

Achievements

by